

Resource Summary Report

Generated by [dkNET](#) on Aug 11, 2026

Brilliant Violet 421(TM) anti-human CD3

RRID:AB_2565849

Type: Antibody

Proper Citation

BioLegend Cat# 317344, RRID:AB_2565849

Antibody Information

URL: http://antibodyregistry.org/AB_2565849

Proper Citation: BioLegend Cat# 317344, RRID:AB_2565849

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_2565849

Vendor: BioLegend

Catalog Number: 317344

Alternative Catalog Numbers: 317343

Record Creation Time: 20250820T041009+0000

Record Last Update: 20250820T181355+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ruan Z, et al. (2026) Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy. Med (New York, N.Y.), 7(4), 101026.

Pi R, et al. (2025) NKp30 and NKG2D contribute to natural killer cell-mediated recognition of HIV-infected cells. iScience, 28(10), 113548.

da Silva Bortoleti BT, et al. (2025) A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors. Nature communications, 16(1), 9915.

He S, et al. (2025) Systemic immune activity occurs during human immune system maturation. Cell, 188(25), 7291.

Wong YC, et al. (2025) An open-label study on the safety and immunogenicity of a PD-1-enhanced DNA vaccine used as a T cell booster for COVID-19. EBioMedicine, 115, 105699.

Hammer Q, et al. (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell stem cell, 31(9), 1376.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. Cell reports. Medicine, 5(2), 101421.

Tang F, et al. (2023) A pan-cancer single-cell panorama of human natural killer cells. Cell, 186(19), 4235.

Gamradt S, et al. (2021) Reduced mitochondrial respiration in T cells of patients with major depressive disorder. iScience, 24(11), 103312.

Willcox CR, et al. (2019) Butyrophilin-like 3 Directly Binds a Human V α 4+ T Cell Receptor Using a Modality Distinct from Clonally-Restricted Antigen. Immunity, 51(5), 813.